The company’s platform uses machine learning and metabolomics to identify new compounds. Enveda will use the financing to advance the leading compounds to the clinical stage, according to a Dec. 21 Enveda news release.
Dimension led the funding round that brought the company’s total capital raised to $124 million.
“While we are prioritizing building and advancing our internal pipeline, we will continue to forge partnerships with industry-leading pharmaceutical and biotech companies in a variety of therapeutic areas, including inflammation, fibrosis, and other chronic diseases.” Enveda Chief Business Officer Vanitha Sekar, PhD, said.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
